Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCND1 | P24385 | 16/20 | 0.84 |
| ▸ | CDK6 | Q00534 | 13/20 | 0.84 |
| ▸ | CDK4 | P11802 | 10/20 | 0.68 |
| ▸ | CDK2 | P24941 | 4/20 | 0.50 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.50 |
| ▸ | CSF1R | P07333 | 2/20 | 0.50 |
| ▸ | CCNK | O75909 | 1/20 | 0.50 |
| ▸ | CDK7 | P50613 | 1/20 | 0.50 |
| ▸ | CDK9 | P50750 | 1/20 | 0.50 |
| ▸ | CCNH | P51946 | 1/20 | 0.50 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.50 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.50 |
| ▸ | CCND3 | P30281 | 3/20 | 0.49 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24322142 | 1.00 | CCND1 (0.84) | CCND1CDK6CDK4CDK2CCNA2 | |
| SCHEMBL29514902 | 0.96 | CCND1 (0.80) | CCND1CDK6CDK4CDK2CCNA2 | |
| SCHEMBL29515094 | 0.96 | CCND1 (0.78) | CCND1CDK6CDK4CDK2CCNA2 | |
| SCHEMBL30541022 | 0.93 | CCND1 (0.80) | CCND1CDK6CDK4CDK2CCNA2 | |
| SCHEMBL25235177 | 0.93 | CCND1 (0.80) | CCND1CDK6CDK4CDK2CCNA2 | |
| SCHEMBL24322062 | 0.92 | CDK6 (0.79) | CCND1CDK6CDK4CDK2CCNA2 | |
| SCHEMBL24322177 | 0.92 | CCND1 (1.00) | CCND1CDK6CDK4CDK2CCNA2 | |
| SCHEMBL25282784 | 0.92 | CCND1 (0.82) | CCND1CDK6CDK4CDK2CCNA2 | |
| SCHEMBL24322173 | 0.90 | CCND1 (1.00) | CCND1CDK6CDK4 | |
| SCHEMBL25278621 | 0.90 | CCND1 (0.76) | CCND1CDK6CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4214213-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | Prelude Therapeutics, Incorporated (US) | 2023-07-26 | — | — | EP | claimed |
| WO-2022061273-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2022-03-24 | — | — | WO | claimed |
| US-20250197418-A1 | Polymorphic Compounds And Uses Thereof | PRELUDE THERAPEUTICS INC (US) | 2025-06-19 | — | — | US | disclosed |
| CN-119421884-A | Polymorphic compounds and uses thereof | 普莱鲁德疗法有限公司 | 2025-02-11 | — | — | CN | disclosed |
| EP-4496627-A1 | POLYMORPHIC COMPOUNDS AND USES THEREOF | Prelude Therapeutics Incorporated (US) | 2025-01-29 | — | — | EP | disclosed |
| WO-2023178547-A1 | POLYMORPHIC COMPOUNDS AND USES THEREOF | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2023-09-28 | — | — | WO | disclosed |
| EP-4214213-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | Prelude Therapeutics, Incorporated (US) | 2023-07-26 | — | — | EP | disclosed |
| WO-2022061273-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2022-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250197418-A1 | Polymorphic Compounds And Uses Thereof | CDK6, CDK4, CDK8 | CCND1 69/4885CDK6 1/4885CDK4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.